The Department of Justice has filed a False Claims Act complaint against Regeneron Pharmaceuticals, a New York-based pharmaceutical company, over allegedly inflating Medicare reimbursement rates for Eylea, an injection therapy approved for retinal diseases.
It was approved by the Food and Drug Administration to treat, among other conditions, neovascular age-related macular degeneration.
WHAT’S THE IMPACT
